

# INDEX

## A

ACPH. See air changes per hour (ACPH)

active pharmaceutical ingredient (API)

- administering, 141
- concentrated hormone solutions, 121
- C-PEC required for compounding, 79, 81
- decontamination and cleaning, 145
- defined, 20, 115
- environmental monitoring, 149
- facility design/requirements, 91, 93, 94, 96–97, 98
- PPE, 39, 40–44
- risk assessment, 23, 26
- spills, 155
- storage of, 65, 66, 68–69, 72
- transporting, 139
- weighing, in BSC, 120

ADC. See automated dispensing cabinet (ADC)

administering HDs, 141–144

- chemo, 142–143
- chemo-certified nurse for, 144
- crushing HDs, 142
- CSTDs, 142–143
- diluent to be mixed with the drug just prior to, 143
- IM methotrexate, 142
- non-antineoplastic drugs, 143
- nursing competencies, 143
- to patients in an outpatient infusion setting, 143
- PPE, 141
- stat oxytocin drip, 143

air changes per hour (ACPH)

- anterooms, 101
- calculating, 97–98
- compounding facilities, 91, 92, 93, 96, 97–98, 117, 167
- C-PEC, 85, 86
- C-SCA, 86, 97–98, 106–107
- C-SEC, 79, 102–103, 181, 182
- defined, 91
- flammable cabinets, 68, 70
- storage requirements, 65, 116

ambulatory patients, dispensing finished dosage forms to, 136–137

American Society for Testing and Materials (ASTM)

- Standard ASTM F739 for gloves, 47
- Standard D6978 for gloves, 29, 39, 40, 47, 48–49, 76, 167, 169

Standard F739-99a for testing gloves for permeation to general chemicals, 47

Standard F3267 for gowns, 49

American Society of Health-System Pharmacists (ASHP)

- ASHP Guidelines on Handling Hazardous Drugs*, 18, 51, 115, 153, 155, 156, 165
  - ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs*, 18
  - ASHP Technical Assistance Bulletin on Handling Cytotoxic Drugs in Hospitals*, 3
  - Assessment of Risk Toolkit, 30
  - Compounding Resource Center, 115, 159
  - Pharmacy Competency Assessment Center, 33, 34, 143
  - Sterile Compounding certificate program, 33
- American Society of Heating, Refrigerating, and Air-Conditioning Engineers (ASHRAE), 80, 83, 96
- answer key, 180–187

- OSHA-recommended steps for treatment of workers with skin or eye contact with HDs, 187
- recommendations for compounding and handling nonsterile HD dosage forms, 181
- recommendations for spill cleanup procedure, 186–187
- recommendations for use of class II BSCs, 181–182
- recommendations for use of class II BSCs and CACIs, 182–183
- recommendations for use of gloves, 184
- recommendations for use of gowns, 184
- recommendations for working in any C-PEC, 185
- recommended contents of HD spill kit, 186

anteroom, 101

- ACPH, 79, 91, 97–98, 101, 102, 167
- check of chemo items occurring in, 122
- cleaning, 146
- cleanroom suite, 106, 107
- corrugated cardboard in, 124
- C-SCA, 101, 107
- decontaminating, 146
- facility design/requirements, 101, 103
- floor drains, 113
- ISO 7, 79, 85, 94, 101, 102, 106
- negative pressure, 101, 102, 106
- PPE, 42, 50

API. See active pharmaceutical ingredient (API)

aseptic technique

- Bacillus Calmette-Guérin*, 121
- defined, 169

eye protection and respirators, 170  
 needles and syringes, 126  
 PPE, 169–170  
 ASHP. See American Society of Health-System Pharmacists (ASHP)  
 ASHRAE. See American Society of Heating, Refrigerating, and Air-Conditioning Engineers (ASHRAE)  
 Assessment of Risk Toolkit (ASHP), 30  
 ASTM. See American Society for Testing and Materials (ASTM)  
 automated dispensing cabinet (ADC), 71, 132, 135  
 availability of USP <800>, 1

## B

Bacillus Calmette-Guérin (BCG), 121, 122  
 BCG. See Bacillus Calmette-Guérin (BCG)  
 beyond-use dates (BUDs), 85, 86–87, 102–104, 129  
 biological safety cabinet (BSC)  
   alarm for malfunctioning, 88  
   antineoplastic agents, 105  
   aseptic technique, 169  
   Bacillus Calmette-Guérin, 121  
   biological preparations in, 121  
   canopy connection, 88, 103  
   certification of, 84, 100  
   classes of, 87–88 (See also BSC classes)  
   cleaning, 146, 147, 170–171  
   in cleanroom suite, 106  
   dosing of antineoplastics, 131  
   emergency power, 113  
   environmental monitoring, 150  
   exhaust, 103  
   eye and respiratory protection, 170  
   eye protection, 53, 170  
   facility design/requirements, 168  
   gloves, 48, 170  
   labeling chemo pre-meds, 119  
   labeling non-chemo pre-meds, 122  
   low use exemption, 4, 90  
   methotrexate, 29, 119–120, 142  
   negative pressure cleanroom, 87  
   non-antineoplastic HDs, 84  
   nonsterile compounds prepared in a negative pressure room in, 82  
   nonsterile HDs, compounding, 168  
   on NSF Certified Biosafety Cabinetry list, 84  
   opening packages in, 58–59  
   packaging in, 29, 75, 81, 131–132, 133, 134, 135  
   perimeter around, in C-SCA, 107, 108  
   PPE, 44  
   reconstituting HDs, 126, 143  
   respiratory protection, 43, 54, 55, 170  
   robotic devices, 83, 168, 169  
   shoe covers, 52  
   stat meds for urgent patient situations, 124  
   sterile compounding in, 78, 80  
   sterile HDs, compounding, 168  
   total exhaust, 88  
   transferring HD to IV bag, 126  
   weighing APIs, 120  
   what was allowed in 2008 <797> and what is allowed in <800> and 2023 <797>, 77, 93  
   wipe samples collected in, 150  
 Biosafety Cabinetry Certification (NSF/ANSI 49), 88  
 BSC. See biological safety cabinet (BSC)  
 BSC classes  
   Class I, 58–59, 79, 82, 87, 168  
   Class II, 78, 83, 84, 87–88, 100, 103, 121, 126, 168, 181–182  
   Class III, 87, 168, 182–183  
   types of, 87  
 BUDs. See beyond-use dates (BUDs)  
 buffer room  
   ACPH, 79, 97–98, 102, 121  
   BCG compounded in, 121  
   check of chemo items occurring in, 122  
   cleaning, 146  
   in a cleanroom suite, 106, 107  
   counting and packaging HDs, 75  
   C-PEC, 86  
   decontaminating, 146  
   engineering controls, 77, 79, 85, 86, 87, 102–103, 168  
   eyewash stations in, 113  
   facility design/requirements, 91, 92, 93–94, 96–100, 103, 167  
   HEPA-filtered air in, 97  
   ISO 7, 79, 94, 101, 102, 104–105, 106  
   low volume exemption, 111  
   negative pressure, 101, 104, 106  
   pass-through chambers, 108, 110  
   PPE, 42, 45, 50, 51, 52, 170  
   presterilization procedures, 120  
   receiving personnel, 58, 59, 63  
   refrigerator and freezer placement, 110, 111, 112  
   storage of HDs, 66, 68, 69, 70, 71, 73  
   for weighing powders, 101–102

## C

CACI. See compounding aseptic containment isolator (CACI)  
 CAGs. See Certification Application Guides (CAGs)  
 carmustine, 49  
 carousels, 72

- CDC. See Centers for Disease Control and Prevention (CDC)
- Center for Biologics Evaluation and Research (CBER), 19, 121, 122
- Center for Drug Evaluation and Research (CDER), 19, 121, 122
- Center for Improvement in Healthcare Quality (CIHQ), 1
- Centers for Disease Control and Prevention (CDC)
- hand hygiene defined by, 39–40
  - Hand Hygiene Guidance, 40
- Centers for Medicare & Medicaid Services (CMS), 21, 29, 125, 133–134
- certification
- administering monoclonal antibody, 144
  - BSC, 84, 100
  - CETA Certification Application Guides (CAGs), 102–103
  - C-PEC, 100, 117, 150
  - C-SEC, 100, 117, 150
  - hoods, 100
- Certification Application Guides (CAGs), 102–103
- CETA. See Controlled Environment Testing Association (CETA)
- chemo agents
- administering, 142–143
  - certification for administering monoclonal antibody, 144
  - CSTDs for administering, 142
  - dispensing finished dosage forms to ambulatory patients, 136
  - exposure, 17
  - eye protection, 53
  - face shields, 53
  - feeding tube for administering, 142–143
  - head and beard covers used for, 52
  - need for <800>, 12
  - personnel, 15
  - pregnant or breast-feeding pharmacy technicians, 31–32
  - recording lot numbers for, 124
  - respirator, 55
  - shoe covers used for, 52
  - transport of, by volunteers, 139
- chemo bag, 45, 46, 58, 59, 72, 135
- chemo-certified nurse, 144
- chemo gloves. See gloves
- chemo gown, 45, 46, 50, 51
- chemo hood, 35, 111, 134, 145, 147–148, 168. See also containment primary engineering control (C-PEC)
- chemo infusion center, 122
- chemo mat, 58
- chemo room
- anteroom to, 101, 110
  - cart pass-through in, 110
  - doffing garb in, 122
  - HD totes delivered to, 59
  - nonsterile chemo drugs stored in, 68
  - pass-through chambers, 109–110
  - pass-through refrigerator in, 110
  - taking HD packages into, 59
  - unpacking the wholesaler tote in, 58
- chloramphenicol, 89
- Class I BSCs, 58–59, 79, 82, 87, 168
- classified rooms, 96
- Class II BSCs, 78, 83, 84, 87–88, 100, 103, 121, 126, 168, 181–182
- Class III BSCs, 87, 168, 182–183
- cleaning. See decontamination and cleaning
- cleanroom suite
- ACPH, 97–98, 117
  - approval to build, 112
  - BSC, 87, 106, 120
  - CACI, 106
  - corrugated cardboard in, 124
  - engineering controls, 77, 85, 86, 87, 102–107
  - facility design/requirements, 92, 93–94, 96, 97–98, 106, 112
  - HEPA-filtered air in, 97
  - instead of C-SCA, 104
  - negative pressure, 87
  - negative pressure cleanroom compared to C-SEC, 106
  - pass-through chambers, 108, 109
  - PPE, 45, 51, 52
  - printer in, 112
  - receiving personnel, 58, 59–60
  - refrigerator and freezer placement, 110
  - refrigerator in, 112
  - shelving in, 112
  - spills, 156
- closed system drug-transfer device (CSTD), 89–90
- in <800> vs. other USP chapters, 4, 78
  - administering chemo, 142–143
  - administering HDs, 89, 142–143
  - antineoplastics, 143
  - chloramphenicol, 89
  - compounding HDs, 89
  - defined, 77, 79, 89, 168–169
  - FDA approval of, 90
  - incompatibility with specific HDs, 90
  - in isolator, 123
  - low use exemption allowed in 2008 <797>, 90
  - more than just antineoplastic drugs, 89–90
  - negative pressure technique, 124, 126
  - NIOSH performance protocol for, 90
  - non-chemo agents, 125
  - nursing vs. pharmacy use of, 90

- ONB code, 90
- using instead of a hood for occasional HD compounding, 90
- when compounding in a CACI, 89
- CMS. See Centers for Medicare & Medicaid Services (CMS)
- competence, documenting, 34–35
- competence assessment exam, 177–179
- Competence Assessment Tools for Health-System Pharmacies* (Murdaugh), 33, 34, 143, 165, 166, 168, 170
- competence checklist, 175–176
- compounded sterile preparation (CSP)
  - chemo and non-HD CSPs compounded in the same C-PEC, 85
  - decontaminating, 115, 148
  - PPE, 41, 42, 48, 122, 135, 169
  - transporting, 135
- compounding aseptic containment isolator (CACI). See also containment primary engineering control (C-PEC)
  - alarm for malfunctioning, 88
  - antineoplastic agents compounded in, 105
  - aseptic technique, 169
  - beyond-use dates (BUDs), 87, 96
  - BSC used instead of, 78
  - cleaning, 146, 147, 170–171
  - in cleanroom suite, 106
  - CSTDs used when compounding in, 89
  - emergency power, 113
  - eye protection, 53, 170
  - facility design/requirements, 168
  - gloves, 48, 170
  - head/hair/shoe covers, 42, 52
  - installed in a segregated room, 86
  - low use exemption, 4
  - in a negative pressure room, 85, 86, 87, 104–105
  - for non-antineoplastic HDs, 84
  - non-externally vented, for preparing oral HDs, 82
  - packaging, 131–132, 135
  - perimeter around, in C-SCA, 107, 108
  - placement of, 92
  - in a positive pressure room, 77–78, 97
  - PPE, 44
  - RABS compared to, 83
  - reconstituting HDs, 126, 143
  - respiratory protection, 43, 54, 55, 170
  - robotic devices, 83, 168, 169
  - shoe covers, 52
  - to split methotrexate tablets, 119–120
  - transferring HD to IV bag, 126
  - vents outside of, 104
  - what was allowed in 2008 <797> and what is allowed in <800>, 102
  - what was allowed in 2008 <797> and what is allowed in <800> and 2023 <797>, 77, 93
  - wipe samples collected in, 150
- compounding aseptic isolator (CAI), 83, 85, 86, 106, 178
- compounding HDs, 115–127, 165–171
  - alcohol, spraying, 123
  - alcohol gel instead of washing hands, 124
  - API, 115
  - aseptic technique, 169–170
  - BCG, 121
  - biologics not listed on the NIOSH HD list, 122
  - BSCs, 121
  - check of chemo items, 122
  - compounded topical cream, 121
  - compounding non-HDs in the negative pressure hood and room, 119
  - compounding nonsterile HDs in an open room, 119
  - concentrated hormone solutions, 121
  - corrugated cardboard, 124
  - crushing tablets to make a solution, 119
  - CSTDs, 123, 124, 125
  - CVE, 119–120
  - definition of HDs, 166
  - disposable mortar and pestle, 124
  - emergent need for, 124–125
  - facility design/requirements, 167–169
  - learning objectives, 165
  - lot numbers for chemo, 124
  - medical surveillance program, 171
  - methotrexate, 119–120
  - negative pressure technique, 126–127
  - non-antineoplastic hazardous oral solutions, 119
  - nonsterile, non-antineoplastic hazardous medications, 119
  - outside of the proper facility, 125
  - overview, 165–166
  - plastic-backed preparation mat, 122–123
  - policies required and recommended in USP <800>, 115–118
  - PPE, 122
  - precautions, 166–167
  - pre-saturated gauze to disinfect vials, 123
  - vs. regular compounding, 124
  - spray bottles of cleaners, 123
  - weighing out HD APIs in a BSC, 120
  - when is a HD not a HD, 120
  - work practices, 170–171
- Compounding Resource Center (ASHP), 115, 159
- containment primary engineering control (C-PEC), 78–88
  - ACPH, 85, 86
  - acrylic glove boxes, 85

- BSCs, 84, 87–88
- in a buffer room, 86
- buying, 84
- CACI, 83, 85, 86–87
- certification, 100, 117, 150
- chemo and non-HD CSPs compounded in the same, 85
- classified rooms for sterile compounding, 96
- compliant for compounding nonsterile HDs, 79
- compliant for compounding sterile HDs, 83
- compounding chemo and non-HD CSPs in the same, 85
- counting and packaging HDs, 75
- crushing tablets in, 119
- C-SCA, 79, 87, 106, 108
- C-SEC, 79, 102, 103
- CSPs, 84, 85
- CVE, 78, 99
- defined, 77, 78
- facility design/requirements, 92, 96, 97, 98, 99
- HEPA filters, 85
- LAFW, 86
- laminar air flow hoods, 84
- mixing chemo pre-meds in a hood, 85
- for nonsterile compounding, 79–83, 117
- placing a regular hood in the negative pressure cleanroom to mix pre-meds, 86
- policies required and recommended, 117, 118
- PPE, 41–42, 45–46, 48, 53, 54, 55, 99
- presterilization procedures, including weighing and mixing, 101–102
- RABS, 83
- receiving personnel, HD precautions for, 58–59, 61
- for sterile compounding, 83–88, 117
- storage of HDs, 73
- uninterrupted power source for, 113, 117
- venting, 83–84, 85
- containment secondary engineering control (C-SEC), 102–106
  - ACPH, 79, 102–103, 181, 182
  - certification of, 100, 117, 150
  - cleaning, 146
  - cleanroom compared to, 106
  - C-PEC placed in, 79, 102
  - C-SCA compared to, 77, 78, 103
  - defined, 77, 106
  - facility design/requirements, 102–106
  - HEPA-filtered air in, 103
  - negative pressure cleanroom compared to, 106
- containment segregated compounding area (C-SCA), 106–108
  - in <797> vs. C-SCA in <800>, 106–107
  - ACPH, 86, 97–98, 106–107
  - as an area and not a room, 106
  - anteroom in, 101, 107
  - BUDs, 86, 96, 103, 105, 129
  - chemo mixed in, 94
  - cleaning, 146
  - cleanroom instead of, 104
  - corrugated cardboard in, 124
  - C-SEC compared to, 77, 78, 103
  - CVE compounding in, 105
  - decontaminating, 146
  - defined, 79, 106
  - example of room requirements, 107, 108
  - facility design/requirements, 86–87, 91, 92, 93–94, 103
  - HEPA-filtered air in, 97–98, 106, 107, 112
  - ISO classification required for, 96
  - low use exemption, 5
  - negative pressure cleanroom compared to, 106
  - as a negative pressure room, 107
  - packaging HDs, 75
  - perimeter of, 107
  - personal protective equipment for, 42, 45, 50, 51, 52
  - printer in, 112
  - receiving HDs, 58, 59, 63
  - refrigerator in, 112
  - shelving in, 112
  - sink placement, 98–99
  - sterile HDs mixed in, 96
  - storage of HDs, 70, 73
  - un-gowning area, 105, 107
  - what was and wasn't allowed in the 2008 version of <797> and in <800>, 102
- containment strategies, in <800>, 5. *See also* engineering controls; personal protective equipment (PPE); work practices
- containment ventilated enclosure (CVE)
  - buying, 80
  - compliant for compounding nonsterile HDs, 79
  - defined, 78
  - environmental monitoring, 149
  - HEPA-filtered air in, 78
  - methotrexate tablets in, 81, 119–120
  - for non-hazardous compounding, 105
  - nonsterile compounds be prepared in, 82
  - opening packages in, 58–59
  - packaging in, 131–132, 133, 134
  - turning off, 99
  - weighing and mixing in, 101–102, 120
- contamination, finding, 150, 151
- Controlled Environment Testing Association (CETA), 102–103
- corrugated cardboard, 124

counting and packaging HDs, 75–76  
 automated packaging machines, 75  
 community pharmacy, 76  
 manufacturer unit-dose or unit-of-use packages, 75–76  
 unit-dose solid oral antineoplastics, 75

C-PEC. See containment primary engineering control (C-PEC)

crushing HDs, 142

C-SCA. See containment segregated compounding area (C-SCA)

C-SEC. See containment secondary engineering control (C-SEC)

CSP. See compounded sterile preparation (CSP)

CSTD. See closed system drug-transfer device (CSTD)

CVE. See containment ventilated enclosure (CVE)

cyclophosphamide, 122, 150

## D

decontamination and cleaning, 145–148  
 agents used for, 145  
 alcohol used for, 148  
 cleaning guidelines under USP <800>, 146  
 cleaning supplies required by USP <800>, 148  
 deactivation, 146, 147  
 decontaminating and cleaning schedule, 147  
 dilutions of decontamination and cleaning solutions, 147  
 disinfection, 145, 146–147, 148  
 floors, 148  
 mops, 148  
 wipe sampling, 148

designated person, 32–33, 151

diluent to be mixed with the drug just prior to administering HDs, 143

dispensing HDs, 135–137  
 finished dosage forms to ambulatory patients, 136–137  
 finished dosage forms to patient care units, 135–136

disposable mortar and pestle, 124

disposal, 4, 8, 11, 14, 27, 116, 118, 153, 171  
 acknowledgment of HD risk form, 37  
 hazardous waste disposal bags, in spill kit, 186  
 noninjectable dosage forms of HDs, 181  
 personnel training, 33, 57  
 supply and drug waste in the class III BSC, 183  
 of used PPE, 8, 117

DNV Healthcare, 1

donning and doffing, 39, 45–46  
 defined, 39  
 order of, 45–46

## E

engineering controls, 77–88  
 BSC for sterile compounding, 78  
 CACI, 78  
 C-PEC, defined, 78  
 C-PEC for nonsterile compounding, 79–83  
 C-PEC for sterile compounding, 83–88  
 C-SCA, 79  
 C-SEC, 79  
 CVE, 78  
 general information, 77–79  
 HEPA filters, 79  
 PECs, 77, 79  
 SECs, 77–78, 79  
 types of, 77–79

entity, 3

environmental monitoring, 149–151  
 contamination, finding, 150, 151  
 drugs commonly assayed, 150  
 microbial monitoring, 149  
 quality assurance and quality control activities, 149  
 surface sampling, 149–150, 151  
 using an isolator instead of a BSC, 150  
 wipe samples, 150, 151

Environmental Protection Agency (EPA), 3, 12, 82, 146, 147, 153, 166

EPA. See Environmental Protection Agency (EPA)

estrogens, 22, 67

exhaust air, 97

exposure  
 chemo agents, 17  
 developing policies, 115  
 double-gloving, 29  
 final dosage forms as being safer than powders, 18  
 HD defined by, 18  
 nursing competencies, 143  
 PPE available to receiving personnel, 60  
 PPE worn based on the dosage form administered, 141  
 PPE worn by nurse when crushing HDs, 142  
 PPE worn by personnel who are administering HDs, 43  
 types of, 17–18

eye protection, 53–54  
 aseptic technique, 170  
 face shield, 53  
 goggles, 53  
 meaning of, 53  
 prescription eyeglasses as, 53  
 when cleaning HD areas outside a C-PEC, 53  
 when cleaning the area inside a BSC or CACI, 53  
 when cleaning up a spill, 54

when mixing chemo, 53  
when to use, 53

## F

facility design/requirements, 91–113, 167–169  
  anteroom, 101, 103  
  BSC, 168  
  buffer room, 91, 92, 93–94, 96–100, 103, 167  
  CACI, 168  
  certification of engineering controls, 100  
  cleanroom suite, 92, 93–94, 96, 97–98, 106, 112  
  for compounding nonsterile HDs, 168  
  for compounding sterile HDs, 168–169  
  C-PEC, 92, 96, 97, 98, 99  
  C-SCA, 106–108  
  C-SEC, 102–106  
  emergency power, 113  
  eyewash stations, 113  
  finishes for the floors, walls, and ceilings, 112–113  
  freezers, 110–111  
  general information, 91–100  
  HEPA-filtered air, 92  
  ISO 7, 92  
  low volume exemption eliminated from 2023 797, 111–112  
  pass-through chambers, 108–110  
  pre-sterilization areas for weighing powders, 101–102  
  printers, 112  
  refrigerators, 110–111, 112  
  shelving, 112  
  sinks, 112  
  storing and compounding HDs, 167–168  
  USP <795>, 92, 93, 98, 112, 113  
  USP <797>, 92, 93, 98, 112, 113  
  USP <800>, 91–113  
FDA. See U.S. Food and Drug Administration (FDA)  
finished dosage forms, dispensing  
  to ambulatory patients, 136–137  
  to patient care units, 135–136  
fluorouracil, 28, 67, 150  
fosphenytoin, 13, 124  
freezers, 110–111, 112

## G

general principles of USP <800>, 3–5  
gloves, 47–49  
  changing, 49  
  chemo-rated, 47  
  double-gloving, 29, 47–48  
  how to sterilize, 47

  isolator gloves, 48  
  permeability of, 49  
  standards for, 47  
  sterile chemo gloves, 47, 48  
  tested per ASTM D6978 and lab chemical tested per ASTM F739, 47  
  tested to meet ASTM standard D6978, 40  
  use with carmustine or thiotepa, 49  
  when handling non-antineoplastic HDs, 47  
  when to use sterile gloves, 47  
  when working in a compounding isolator, 48  
  working inside a CACI, 48  
gowns, 49–51  
  blue vs. yellow, 50  
  changing, 51  
  chemo-rated, 49  
  construction of, 50  
  hanging in the anteroom for use later in the day, 50  
  material used for, 50  
  permeability of, 49  
  removed, retained, and used throughout the work shift if it isn't soiled, in 2008 <797> vs. <800>, 50  
  reusable gowns qualified as disposable, 50  
  re-worn during the day if a compounder must leave the HD compounding area, 50  
  standards for, 49  
  un-gowning area inside a negative pressure room, 107  
  use for non-HDs vs. those used for chemo, 49  
  use of a gown throughout one shift, 45  
  washable, 50  
  wearing a regular gown under a chemo gown, 51  
  wearing one vs. two, when compounding, 51  
  when compounding HDs, 45  
*Guidelines on Handling Hazardous Drugs (ASHP)*, 18, 51, 115, 153, 155, 156, 165

## H

hair covers, 42, 52  
hand hygiene, 39–40  
Hand Hygiene Guidance (CDC), 40  
Hazard Communication Plan, 35–37  
hazardous drugs (HDs)  
  administering, 141–144  
  compounding, 115–127, 165–171  
  counting and packaging, 75–76  
  definition of, 18–19, 166  
  dispensing, 135–137  
  identifying, 20  
  letter concerning risks of, 13  
  receiving personnel and, 57–63  
  risk assessment, 23–30  
  storage of, 65–74

transporting, 139  
types of, 19

hazardous waste, 153

HDs. *See* hazardous drugs (HDs)

head covers, 42

heating/ventilating/air conditioning (HVAC), 95, 103

HEPA. *See* high-efficiency particulate air (HEPA)

high-efficiency particulate air (HEPA)

- ACPH, 97–98
- BSC, 87, 88
- BUDs, 102, 103, 112
- C-PEC, 78, 80, 82, 85
- C-SCA, 97–98, 106, 107, 112
- C-SEC, 103
- CVE, 78

facility design/requirements, 92

gases stopped by, 79

pass-through chambers, 99–100, 108, 109–110

pre-filter as, 80

redundant, 80

removing the requirement for, 1

requirements for compounding nonsterile HDs, 168

in series, 80

hoods. *See* also containment ventilated enclosure (CVE)

- buying, 80
- certification, 100
- chemo hoods, 35, 111, 134, 145, 147–148, 168
- cleaning and decontaminating, 148
- laminar airflow, 84
- requirements for, 5, 7, 8, 91, 94
- rusty, 148

human resources, 31–37

- designated person, 32–33
- documenting competence, 34–35
- Hazard Communication Plan, 35–37
- medical surveillance, 31–32
- personnel training, 33–34

---

## I

IARC. *See* International Agency for Research on Cancer (IARC)

ifosfamide, 150

IM methotrexate, 142

*Improving Safe Handling at a Community-Based Health System* (Roussel and Bennie), 159

Insanitary Conditions (FDA), 99–100, 108, 109, 110, 148

International Agency for Research on Cancer (IARC), 19

International Standards Organization (ISO) 5, 96

International Standards Organization (ISO) 7

- air quality standards, 167
- anteroom, 79, 85, 94, 101, 102, 106

- buffer room, 79, 94, 101, 102, 104–105, 106
- cleanroom, 94, 96, 103, 106
- facility design/requirements, 92
- storage in the buffer area, 69

International Standards Organization (ISO) 8, 101, 120

intravenous (IV)

- Assessment of Risk, 25
- bag, 126–127
- checking, 42
- room, 85, 101, 111, 168

intravenous immunoglobulin (IVIG), 85

IPA. *See* isopropyl alcohol (IPA)

ISO 5. *See* International Standards Organization (ISO) 5

ISO 7. *See* International Standards Organization (ISO) 7

ISO 8. *See* International Standards Organization (ISO) 8

isopropyl alcohol (IPA), 126, 127

IV. *See* intravenous (IV)

IVIG. *See* intravenous immunoglobulin (IVIG)

IV room, 85, 101, 111, 168. *See also* containment secondary engineering control (C-SEC)

---

## J

The Joint Commission (TJC), 1, 13

---

## L

LAFW. *See* laminar airflow workbench (LAFW)

laminar airflow workbench (LAFW), 85, 86, 106

low use exemption, 4, 90

---

## M

MABs. *See* monoclonal antibodies (MABs)

*Managing Hazardous Drug Exposures: Information for Healthcare Settings* (NIOSH), 3, 159, 166

- developing policies, 115
- double-gloving, 29
- final dosage forms as being safer than powders, 18
- HD defined by, 18
- nursing competencies, 143
- PPE available to receiving personnel, 60
- PPE worn based on the dosage form administered, 141
- PPE worn by nurse when crushing HDs, 142
- PPE worn by personnel who are administering HDs, 43

material safety data sheets (MSDS), 167. *See also* safety data sheet (SDS)

medical surveillance, 31–32, 171

megestrol, 21, 29, 133

methotrexate, 23, 29, 59, 67, 73, 81, 119–120, 125, 137, 142, 150



microbial monitoring, 149  
 mitomycin, 125  
 monoclonal antibodies (MABs), 21, 25, 144  
 mortar, disposable, 124  
 MSDS. See material safety data sheets (MSDS)

## N

N95 respirator  
   fit-testing for, 55–56  
   need for separate N95 respirator for each person, 56  
   respirators that provide better protection, 54  
   surgical N95 respirator vs. a regular N95 respirator, 55  
   what it does and does not protect against, 54  
   when compounding HDs that could cause a respiratory risk, 42

National Institute for Occupational Safety and Health (NIOSH). See also NIOSH List of Hazardous Drugs in Healthcare Settings  
*Alert*, 3 (See also *Managing Hazardous Drug Exposures: Information for Healthcare Settings* (NIOSH))  
 CSTD defined by, 168–169  
 letter concerning risks of HDs, 13  
 performance protocol for CSTDs, 90  
*Personal Protective Equipment for Health Care Workers Who Work with Hazardous Drugs* (NIOSH), 40, 41, 43, 44  
 Workplace Solutions, 40, 41, 43, 44

National Toxicology Program (NTP), 19

needles and syringes, aseptic technique for, 126

negative pressure requirements, 91

NIOSH. See National Institute for Occupational Safety and Health (NIOSH)

NIOSH List of Hazardous Drugs in Healthcare Settings  
 administering HDs, 144  
 BCG, 121  
 biologics missing from, 122  
 compounding HDs, 121, 122  
 dispensing HDs, 135  
 hazardous waste, 153  
 PPE, 39, 40, 41, 43, 44  
 storage of HDs, 65

non-antineoplastic drugs  
 administering, 143  
 Assessment of Risk, 28, 29, 94, 143  
 BSC for, 84  
 compounded and prepared in a negative pressure environment, 119, 133  
 CSTD required for, 143  
 LAWF or CAI used for, 86  
 PPE, 40, 41, 43, 44, 47, 50  
 receiving personnel, 58  
 storage, 69, 71, 135

NSF/ANSI, 88  
 NSF Certified Biosafety Cabinetry, 84  
 NSF Code of Ethics, 88  
 NTP. See National Toxicology Program (NTP)  
 nursing competencies, 143

## O

occasional nonsterile compounding, 81

Occupational Safety and Health Administration (OSHA), 3  
   fit-testing of respirators, 55–56  
   Hazard Communication Program, 8, 35  
   hazardous chemical standard, 35–36  
   letter concerning risks of HDs, 13  
   Safety and Health Topics, 12  
   SDS, 36, 155  
   training for receiving personnel, 57

ONB code, 90, 126, 182, 183

Oncology Nursing Society (ONS), 3, 31, 32, 43, 141, 143

ONS. See Oncology Nursing Society (ONS)

OSHA. See Occupational Safety and Health Administration (OSHA)

oxytocin, 143

## P

packaging, 131–134. See also counting and packaging HDs

PAPR. See powered air-purifying respirator (PAPR)

pass-through chambers, 99–100, 108–110

patient care units, dispensing finished dosage forms to, 135–136

personal protective equipment (PPE), 39–56  
   administering HDs, 43  
   for administering HDs, 141  
   aseptic technique, 166, 169–170  
   benefits of, 39  
   cleaning up a spill, 44  
   in a cleanroom suite, 45  
   compounding from powders, 42  
   compounding HDs, 41  
   in a compounding room for nonsterile HD preparation, 46  
   C-PEC, 41–42, 45–46, 48, 53, 54, 55, 99  
   crushing HDs, 142  
   C-SCA, 42, 45–46, 50, 51, 52  
   CSP, 41, 42, 48, 122, 135, 169  
   discarding HD trash, 43–44  
   donning and doffing, 39, 45–46  
   eye protection, 53–54  
   general information, 39–46  
   gloves, 47–49  
   gowns, 49–51  
   hair covers, 42, 52

hand hygiene, 39–40

head covers, 42

negative pressure lab, 42

nonsterile vs. sterile compounding, 43

packaging HDs, 41

pharmacist, 42, 45

receiving personnel, 40, 60, 62

requirements, 39, 141

respiratory protection, 54–56 (See also N95 respirator)

reusing, 44

shoe covers, 42, 52

transporting drugs to an infusion area, 43

transporting HDs, 40

using a compounding isolator, 44

*Personal Protective Equipment for Health Care Workers Who Work with Hazardous Drugs* (NIOSH), 40, 41, 43, 44

personnel training, 33–34

- for administering HDs, 143
- antineoplastic contamination, 151
- cleaning the C-SEC, 146
- designated person, 33
- in employee consent form, 37
- frequency of, 34
- HD spill cleanup, 156
- listed in <795>, 34
- listed in <797>, 35
- listed in <800>, 35
- of receiving personnel, 57
- required, 33–34
- surface sampling, 149
- of transport personnel, 135, 136, 139
- to use the chemo hood, 35
- who needs to be trained, 34

pestle, disposable, 124

pharmacist, PPE for, 42, 45

- answering the phone, 42
- checking only items, 45
- checking the preparation compounded in the C-PEC, 42
- completes the checking of a CSP in the anteroom, 42
- counseling a patient, 42

Pharmacy Competency Assessment Center (ASHP), 33, 34, 143

Pharmacy Compounding Accreditation Board, 1

planning, 17–22

- exposure, types of, 17–18
- NIOSH list of HDs, 18–22

plastic-backed preparation mat, 122–123

plastic pouch to contain particles, 142

platinum-based agents, 150

policies, developing, 115

powder containment hood. See containment ventilated enclosure (CVE)

powered air-purifying respirator (PAPR), 43, 44, 54

PPE. See personal protective equipment (PPE)

predominant air, 97

pregnancy

- methotrexate for ectopic pregnancy, 73, 125
- oxytocin as situational hazard to, 143

premixed oxytocin, 143

presterilization areas for weighing powders, 101–102, 120

*Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings* (NIOSH), 3

primary engineering control (PEC), 77, 79, 94, 150.

See also containment primary engineering control (C-PEC)

---

## Q

quality assurance and quality control activities, 149

---

## R

RABS. See restricted access barrier system (RABS)

receiving personnel, 57–63

- boxes of chemotherapy, 63
- broken or damaged HDs, 63
- damaged or broken HD containers, 60
- delivery and acceptance of HDs, 57
- hazardous residue on the outside of packages, 59
- HD precautions for C-PEC, 58–59, 61
- HDs in a negative pressure area, 62
- HDs packaged by suppliers, 62
- HD totes, 59, 62
- ideal process for receiving HDs, 63
- identifying HD containers, 62
- labeling HD containers, 58
- opening HDs, 57–59
- PPE, 40, 60, 62
- pressure monitoring, 59
- receipt of antineoplastics that will be dispensed without manipulation, 59–60
- requirements and recommendations, 61
- training, 57
- unpacking HDs, 58
- where to receive HD shipments, 62
- wholesalers' designation of hazardous items in their ordering system, 62
- wiping the packages of HDs prior to storage, 63

refrigerators, 71, 110–111, 112

requirements, 39

requirements based on the activity performed, 39

requirements based on the dosage form administered, 141

respiratory protection, 54–56. *See also* N95 respirator

- aseptic technique, 170
- fit-testing, 55–56
- meaning of, 54
- surgical masks, 55
- when cleaning up a spill, 56
- when compounding, 55
- when mixing chemo, 55
- when to use, 54
- when unpacking HDs, 55
- when working in a BSC or CACI, 54, 55

restricted access barrier system (RABS), 83

risk assessment, 23–30

## S

*Safe Handling of Hazardous Drugs* (ONS), 31, 32, 43, 141, 143

safety data sheet (SDS), 36, 155, 167

safe work practices, 118

scope of USP <800>, 11–15

- facilities, 15
- handling HDs, 13–14
- necessity of <800>, 11–13
- personnel, 15
- regulations, 14

SDS. *See* Safety Data Sheet (SDS)

secondary engineering controls (SEC), 77, 94, 102, 150.  
*See also* containment secondary engineering control (C-SEC)

sections of USP <800>, 7–10. *See also* USP <800>

- Administering, 9
- Appendix 1: Acronyms, 10
- Appendix 2: Examples of Design for Hazardous Drugs Compounding Areas, 10
- Appendix 3: Types of Biological Safety Cabinets, 10
- Compounding, 9
- Deactivating, Decontaminating, Cleaning, and Disinfecting, 9
- Dispensing Final Dosage Forms, 8–9
- Documentation and Standard Operating Procedures, 9
- Environmental Quality and Control, 8
- Facilities and Engineering Controls, 7–8
- Four tables describe details of particular issues*, 10
- Glossary, 10
- Hazard Communication Program, 8
- Introduction and Scope, 7
- Labeling, Packaging, Transport, and Disposal, 8
- List of Hazardous Drugs, 7
- Medical Surveillance, 9–10
- Personnel Training, 8
- PPE, 8
- Receiving, 8
- References, 10
- Responsibilities of Personnel Handling Hazardous Drugs, 7
- Spill Control, 9
- Types of Exposure, 7

shoe covers, 42, 52

sIPA. *See* sterile 70% isopropyl alcohol (sIPA)

*Small Entity Compliance Guide for Employers That Use Hazardous Chemicals* (OSHA), 35

spill kit, 155–156, 186

spills, 155–157

- API, 155
- cleanroom suite, 156
- personnel training, 156
- policy and procedure, 156, 157
- PPE, 44, 156
- recommendations for spill cleanup procedure, 186–187
- respiratory protection, 56
- responsibility for cleanup, 156
- spill kit, 155–156, 186
- work practices, 155, 171

sterile 70% isopropyl alcohol (sIPA), 47

Sterile Compounding certificate program (ASHP), 33

storage of HDs, 65–74

- in ADCs, 71
- alternative containment strategies for oral antineoplastic agents, 67
- antineoplastic requiring only counting or packaging, 67
- awaiting return to suppliers, 74
- in buffer area, USP <797> and, 69
- in carousels, 72
- chemo agents, 67–68, 70–71
- chemo vials in smooth-coated cardboard boxes, 70
- in community pharmacy, 73
- door signs, 67
- estrogens, 67
- flammable cabinet to store chemo, 70
- injectable medications, 66–67, 73
- intact HDs, 72
- keeping two sets of inventory, 66
- list of hazardous medications that release volatile vapors during storage, 69
- manufacturers' requirement to clean the outer packaging, 66
- methotrexate, 73
- minimum storage requirements, 65
- in negative pressure cabinet located in a neutral area, 70
- in a negative pressure room, 65, 66, 67, 68, 70–71

non-chemo agents, 66  
 non-HD APIs, 66, 68–69  
 nonsterile chemo drugs, 68  
 non-volatile materials, 72  
 in nursing unit, 72  
 oncology support medication stored alongside HD in a C-SCA, 70  
 oral HDs, 67, 73  
 refrigeration, 69–70, 73  
 refrigerator placement for refrigerated antineoplastic HDs, 71  
 saline vials and other similar non-hazardous items, 70  
 “separate,” in <797> storage information, 72  
 separation of HDs and non-HDs, 71  
 transporting inventory that has been received into a negative pressure room, 72–73  
 in vented flammable cabinet, 68  
 supplemental engineering controls, 77, 78, 79. *See also* closed system drug-transfer device (CSTD)  
     defined, 77  
 supply air, 97  
 surface sampling, 149–150, 151

---

## T

*Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs* (ASHP), 18  
*Technical Assistance Bulletin on Handling Cytotoxic Drugs in Hospitals* (ASHP), 3  
 thiotepa, 49  
 TJC. *See* The Joint Commission (TJC)  
 transporting HDs, 139

---

## U

unclassified room, 98  
 uninterrupted power source (UPS), 113  
 United States Pharmacopeia (USP). *See* USP <795>; USP <797>; USP <800>  
 UPS. *See* uninterrupted power source (UPS)  
 U.S. Food and Drug Administration (FDA)  
     CBER, 19, 121, 122  
     CDER, 19, 121, 122  
     Insanitary Conditions, 99–100, 108, 109, 110, 148  
     ONB code, 90, 126, 182, 183  
 USP <795>  
     BUDs, 103, 117, 129  
     cleaning guidelines, 146, 148  
     differences between <800> and, 4  
     environmental monitoring, 149  
     facility design/requirements, 92, 93, 98, 112, 113  
     in full text of USP <800>, 1  
     lot numbers for chemo, 124

    risk assessment, 26, 27  
     for storing and compounding nonsterile HDs, 9  
     training requirements, 33, 34, 116  
     used in conjunction with <800>, 11  
     wording in, 14  
 USP <797>  
     BSCs, 93  
     BUDs, 102–103, 117, 129  
     CACI, 77, 93, 102  
     cleaning guidelines, 146, 148  
     C-SCAs, 102, 106–107  
     differences between <800> and, 4  
     elimination of low volume exemption from 2023 <797>, 111–112  
     environmental monitoring, 149  
     facility design/requirements, 92, 93, 98, 112, 113  
     in full text of USP <800>, 1  
     gowns, 50  
     lot numbers for chemo, 124  
     low-, medium-, and high-risk terminology in, 104  
     low use exemption, 90  
     risk assessment, 26, 27  
     storage in the buffer area, 69  
     for storing and compounding sterile HDs, 9  
     training requirements, 33, 34, 116  
     used in conjunction with <800>, 11  
     wording in, 14  
 USP <800>. *See also* sections of USP <800>  
     administering HDs, 141–144  
     answer key, 180–187  
     availability of, 1  
     BUDs, 129  
     competence assessment exam, 177–179  
     competence checklist, 175–176  
     compounding HDs, 115–127, 165–171  
     containment strategies in, 5  
     contents of sections of, 7–10  
     counting and packaging HDs, 75–76  
     CSTD, 89–90  
     decontamination and cleaning, 145–148  
     dispensing HDs, 135–137  
     engineering controls, 77–88  
     environmental monitoring, 149–151  
     facility design/requirements, 91–113  
     general principles of, 3–5  
     hazardous waste, 153  
     human resources, 31–37  
     low-, medium-, and high-risk terminology in, 104  
     packaging, 131–134  
     planning, 17–22  
     PPE, 39–56  
     receiving personnel and HDs, 57–63

risk assessment, 23–30  
 scope of, 11–15  
 spills, 155–157  
 storage of HDs, 65–74  
 transporting HDs, 139  
 where to start with information from, 159–160

---

## V

valproic acid, 124  
 vented flammable cabinet, 68  
 ventilation systems, 113, 117

---

## W

warfarin, 24, 133  
 water column (wc), 65, 86, 91, 92, 94, 95, 99, 101, 103,  
 104, 106, 167  
 wc. See water column (wc)  
 wipe samples, 150, 151

work practices, 5, 7, 13, 21  
 administering HDs, 141  
 Assessment of Risk, 23, 24, 25, 26, 28, 29  
 compounding HDs, 115, 116, 118, 119, 121, 123,  
 124–125, 170  
 counting and packaging HDs, 75  
 CSTDs, 89, 90  
 decontamination and cleaning, 145, 170–171  
 direct skin or eye contact, 171  
 disposal, 171  
 engineering controls, 77, 81, 82, 84, 86  
 environmental monitoring, 149, 151  
 facility design/requirements, 91, 94, 97, 98, 105  
 human resources, 31  
 packaging, 131, 133  
 PPE, 40–41, 43–44, 51  
 receiving personnel, 57  
 spills, 155, 171  
 storage of HDs, 65, 66, 68, 69  
 transporting HDs, 139





